BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. New therapeutic targets in pancreatic cancer. Cancer Treat Rev 2019;81:101926. [PMID: 31739115 DOI: 10.1016/j.ctrv.2019.101926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Jun E, Koo B, Kim EJ, Hwang DW, Lee JH, Song KB, Lee W, Park Y, Hong S, Shin Y, Kim SC. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer. Biomedicines 2021;9:1599. [PMID: 34829828 DOI: 10.3390/biomedicines9111599] [Reference Citation Analysis]
2 Xu D, Wang Y, Zhou K, Wu J, Zhang Z, Zhang J, Yu Z, Liu L, Liu X, Li B, Zheng J. Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis. Biosci Rep 2020;40:BSR20201087. [PMID: 33169793 DOI: 10.1042/BSR20201087] [Reference Citation Analysis]
3 Tong W, Zhu L, Bai Y, Yang L, Liu Z, Zhang Y. Enhancer RNA LINC00242-Induced Expression of PHF10 Drives a Better Prognosis in Pancreatic Adenocarcinoma. Front Oncol 2022;11:795090. [DOI: 10.3389/fonc.2021.795090] [Reference Citation Analysis]
4 Ricciardiello F, Bergamaschi L, De Vitto H, Gang Y, Zhang T, Palorini R, Chiaradonna F. Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor. Cells 2021;10:431. [PMID: 33670598 DOI: 10.3390/cells10020431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shi H, Li H, Zhen T, Dong Y, Pei X, Zhang X. hsa_circ_001653 Implicates in the Development of Pancreatic Ductal Adenocarcinoma by Regulating MicroRNA-377-Mediated HOXC6 Axis. Mol Ther Nucleic Acids 2020;20:252-64. [PMID: 32193152 DOI: 10.1016/j.omtn.2019.12.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
6 Hua X, Zhang H, Jia J, Chen S, Sun Y, Zhu X. Roles of S100 family members in drug resistance in tumors: Status and prospects. Biomed Pharmacother 2020;127:110156. [PMID: 32335300 DOI: 10.1016/j.biopha.2020.110156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Mashayekhi V, Mocellin O, Fens MHAM, Krijger GC, Brosens LAA, Oliveira S. Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. Theranostics 2021;11:9022-37. [PMID: 34522225 DOI: 10.7150/thno.60350] [Reference Citation Analysis]
8 Manero-Rupérez N, Martínez-Bosch N, Barranco LE, Visa L, Navarro P. The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer. Cells 2020;9:E689. [PMID: 32168866 DOI: 10.3390/cells9030689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Xu T, Xu X, Yang L, Chen X, Ju S. Noninvasive Visualization of Obesity-Boosted Inflammation in Orthotopic Pancreatic Ductal Adenocarcinoma Using an Octapod Iron Oxide Nanoparticle. ACS Appl Bio Mater 2020;3:6408-18. [PMID: 35021772 DOI: 10.1021/acsabm.0c00841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang Y, Zheng Y, Liu X, Ji R, Chen Z, Guo Q, Wu G, Wang Y, Zhou Y. Comprehensive analysis of gene regulation network and immune signatures of prognostic biomarker YAP1 in pancreatic cancer. J Cancer. 2020;11:6960-6969. [PMID: 33123286 DOI: 10.7150/jca.49117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Zhang C, Zou Y, Zhu Y, Liu Y, Feng H, Niu F, He P, Liu H. Three Immune-Related Prognostic mRNAs as Therapeutic Targets for Pancreatic Cancer. Front Med (Lausanne) 2021;8:649326. [PMID: 33869254 DOI: 10.3389/fmed.2021.649326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pham NA, Radulovich N, Ibrahimov E, Martins-Filho SN, Li Q, Pintilie M, Weiss J, Raghavan V, Cabanero M, Denroche RE, Wilson JM, Metran-Nascente C, Borgida A, Hutchinson S, Dodd A, Begora M, Chadwick D, Serra S, Knox JJ, Gallinger S, Hedley DW, Muthuswamy L, Tsao MS. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Sci Rep 2021;11:10619. [PMID: 34011980 DOI: 10.1038/s41598-021-90049-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Hasehira K, Furuta T, Shimomura O, Asada M, Oda T, Tateno H. Quantitative structural analysis of glycans expressed within tumors derived from pancreatic cancer patient-derived xenograft mouse models. Biochem Biophys Res Commun 2021;534:310-6. [PMID: 33288196 DOI: 10.1016/j.bbrc.2020.11.087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tarasiuk A, Mackiewicz T, Małecka-Panas E, Fichna J. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool? Cancer Biol Ther 2021;22:347-56. [PMID: 34224317 DOI: 10.1080/15384047.2021.1941584] [Reference Citation Analysis]
15 Wu P, Wang X, Ma Y, Xu X, Liu W, Sheng Z, Chen M, Zhou R, Zhang K, Goodin S, Zheng X, Li D. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorg Chem 2020;101:104022. [PMID: 32599367 DOI: 10.1016/j.bioorg.2020.104022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Tan B, Huang Y, Zhang B, Lin N. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway. Biomed Pharmacother 2020;128:110133. [PMID: 32447207 DOI: 10.1016/j.biopha.2020.110133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Chen Q, Pu N, Yin H, Zhang J, Zhao G, Lou W, Wu W. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. J Cell Mol Med 2020;24:8674-86. [PMID: 32643277 DOI: 10.1111/jcmm.15500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
18 Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opin Ther Targets 2021;:1-19. [PMID: 34806517 DOI: 10.1080/14728222.2021.2010044] [Reference Citation Analysis]
19 Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu SH, Shukla R, Tomar T, Naji F, McCullumsmith RE. Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia. Int J Mol Sci 2020;21:E8823. [PMID: 33233470 DOI: 10.3390/ijms21228823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li YJ, Wu JY, Wang JM, Xiang DX. Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer. J Control Release 2020;320:105-11. [PMID: 31978441 DOI: 10.1016/j.jconrel.2020.01.041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Guo F, Zhou Y, Guo H, Ren D, Jin X, Wu H. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Cell Death Discov 2021;7:78. [PMID: 33850096 DOI: 10.1038/s41420-021-00462-8] [Reference Citation Analysis]
22 Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer 2021. [PMID: 34262146 DOI: 10.1038/s41416-021-01469-9] [Reference Citation Analysis]
23 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Shopit A, Li X, Wang S, Awsh M, Safi M, Chu P, Jia J, Al-Radhi M, Baldi S, Wang F, Fang J, Peng J, Ma X, Tang Z, Shu X. Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells. Phytomedicine 2021;91:153711. [PMID: 34450377 DOI: 10.1016/j.phymed.2021.153711] [Reference Citation Analysis]
25 Miquel M, Zhang S, Pilarsky C. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:748631. [PMID: 34778259 DOI: 10.3389/fcell.2021.748631] [Reference Citation Analysis]
26 Li X, Qiu N, Li Q. Prognostic Values and Clinical Significance of S100 Family Member's Individualized mRNA Expression in Pancreatic Adenocarcinoma. Front Genet 2021;12:758725. [PMID: 34804125 DOI: 10.3389/fgene.2021.758725] [Reference Citation Analysis]
27 Choi SR, Yang Y, Huang KY, Kong HJ, Flick MJ, Han B. Engineering of biomaterials for tumor modeling. Mater Today Adv 2020;8:100117. [PMID: 34541484 DOI: 10.1016/j.mtadv.2020.100117] [Reference Citation Analysis]
28 Powell-Brett S, Pande R, Roberts KJ. Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:1669. [PMID: 33916294 DOI: 10.3390/cancers13071669] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Takahashi K, Koyama K, Ota Y, Iwamoto H, Yamakita K, Fujii S, Kitano Y. The Interaction Between Long Non-coding RNA HULC and MicroRNA-622 via Transfer by Extracellular Vesicles Regulates Cell Invasion and Migration in Human Pancreatic Cancer. Front Oncol 2020;10:1013. [PMID: 32656089 DOI: 10.3389/fonc.2020.01013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Qu S, Niu K, Wang J, Dai J, Ganguly A, Gao C, Tian Y, Lin Z, Yang X, Zhang X, Liu Z, Li H. LINC00671 suppresses cell proliferation and metastasis in pancreatic cancer by inhibiting AKT and ERK signaling pathway. Cancer Gene Ther 2021;28:221-33. [PMID: 32801328 DOI: 10.1038/s41417-020-00213-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Bu F, Zhu X, Yi X, Luo C, Lin K, Zhu J, Hu C, Liu Z, Zhao J, Huang C, Zhang W, Huang J. Expression Profile of GINS Complex Predicts the Prognosis of Pancreatic Cancer Patients.Onco Targets Ther. 2020;13:11433-11444. [PMID: 33192076 DOI: 10.2147/OTT.S275649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen Q, Pu N, Yin H, Zhang J, Zhao G, Lou W, Wu W. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. Exp Biol Med (Maywood) 2021;:15353702211049220. [PMID: 34632851 DOI: 10.1177/15353702211049220] [Reference Citation Analysis]
33 Uemura S, Wang L, Tsuda M, Suzuka J, Tanikawa S, Sugino H, Nakamura T, Mitsuhashi T, Hirano S, Tanaka S. Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. Biochem Biophys Res Commun 2020;524:378-84. [PMID: 32005519 DOI: 10.1016/j.bbrc.2020.01.105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Takahashi K, Taniue K, Ono Y, Fujiya M, Mizukami Y, Okumura T. Long Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer. Front Mol Biosci 2021;8:717890. [PMID: 34820419 DOI: 10.3389/fmolb.2021.717890] [Reference Citation Analysis]
35 Zhu J, Zhou Y, Zhu S, Li F, Xu J, Zhang L, Shu H. circRNA circ_102049 Implicates in Pancreatic Ductal Adenocarcinoma Progression through Activating CD80 by Targeting miR-455-3p. Mediators Inflamm 2021;2021:8819990. [PMID: 33505218 DOI: 10.1155/2021/8819990] [Reference Citation Analysis]
36 Thomas D, Radhakrishnan P. Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer. Cancers (Basel) 2020;12:E1228. [PMID: 32414222 DOI: 10.3390/cancers12051228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Zhuang H, Chen X, Wang Y, Huang S, Chen B, Zhang C, Hou B. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq. Cancer Immunol Immunother 2021. [PMID: 34279685 DOI: 10.1007/s00262-021-03019-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res 2022;41:56. [PMID: 35139879 DOI: 10.1186/s13046-022-02273-w] [Reference Citation Analysis]
39 Xu K, Qiu Z, Xu L, Qiu X, Hong L, Wang J. Increased levels of circulating circular RNA (hsa_circ_0013587) may serve as a novel biomarker for pancreatic cancer. Biomark Med 2021;15:977-85. [PMID: 34289738 DOI: 10.2217/bmm-2020-0750] [Reference Citation Analysis]
40 Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Cancers (Basel) 2020;12:E3096. [PMID: 33114159 DOI: 10.3390/cancers12113096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Mohamed Abd-El-Halim Y, El Kaoutari A, Silvy F, Rubis M, Bigonnet M, Roques J, Cros J, Nicolle R, Iovanna J, Dusetti N, Mas E. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine 2021;71:103541. [PMID: 34425307 DOI: 10.1016/j.ebiom.2021.103541] [Reference Citation Analysis]